REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 29/03/2019 >View issuer details

2021.05.17 | 16:00 | Permanent Information Releases / General Company News

puce Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children - HTML (w)

2021.05.17 | 16:00 | Permanent Information Releases / General Company News

puce Les données d’un essai pivot présentées au Congrès 2021 de l’ATS montrent que Dupixent® (dupilumab) réduit significativement les crises d’asthme chez l’enfant et améliore sa fonction respiratoire - HTML (w)

2021.05.17 | 07:30 | Permanent Information Releases / General Company News

puce Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial - HTML (w)

2021.05.17 | 07:30 | Permanent Information Releases / General Company News

puce L’essai de phase II du candidat-vaccin contre la COVID-19 de Sanofi et GSK induit une forte réponse immunitaire chez les adultes, toutes tranches d’âge confondues - HTML (w)

2021.05.06 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research - HTML (w)

2021.05.06 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi noue une collaboration de trois ans avec Stanford Medicine pour intensifier sa recherche en immunologie - HTML (w)

2021.05.03 | 18:00 | Share History / Voting Rights and Number of Shares

puce Sanofi: Information concerning the total number of voting rights and shares - March 2021 - HTML (w)

2021.05.03 | 18:00 | Share History / Voting Rights and Number of Shares

puce Sanofi: Informations relatives au nombre total de droits de vote et d’actions - Mars 2021 - HTML (w)

2021.04.30 | 17:56 | Permanent Information Releases / General Company News

puce Annual General Meeting of April 30, 2021 - HTML (w)

2021.04.30 | 17:56 | Permanent Information Releases / General Company News

puce Assemblée Générale Annuelle du 30 avril 2021 - HTML (w)

2021.04.28 | 07:30 | Periodic information / 1st Quarter Information

puce Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER - HTML (w)

2021.04.28 | 07:30 | Periodic information / 1st Quarter Information

puce Sanofi poursuit sa trajectoire de croissance. Forte hausse du BNPA des activités(1) au T1 2021 à TCC - HTML (w)

2021.04.26 | 08:00 | Permanent Information Releases / General Company News

puce Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial - HTML (w)

2021.04.26 | 08:00 | Permanent Information Releases / General Company News

puce Un essai de phase III montre que le nirsevimab protège les nourrissons en bonne santé contre les infections causées par le virus respiratoire syncytial - HTML (w)

2021.04.23 | 16:05 | Permanent Information Releases / General Company News

puce New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 3076